SYRE MEXC RealStocks
Own real SYRE shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-17 22:24:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Spyre Therapeutics, Inc. (SYRE) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $93.89, with a market capitalization of $9.88B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $23.01 to $110.64. This page covers its latest market performance, valuation, price trends and company information.
$9.88B | |
$98.70 | |
$100.97 | |
$85.71 | |
$99.37 | |
932.78K | |
1.27M | |
-- | |
$110.64 | |
$23.01 | |
-- | |
-- |
Spyre Therapeutics, Inc. (SYRE) is trading at $93.89 in after-hours trading as of 2026-11-17 21:58:00, unchanged from the regular-session close of $93.89.
After-hours trading shows how investors are pricing SYRE after the regular session closes. The current after-hours price is near the regular-session close, indicating neutral after-hours sentiment.
Over the past seven days, Spyre Therapeutics, Inc. (SYRE) moved from $103.86 to $93.89, representing a decline of 9.60% ($9.97).
The stock traded between $85.71 and $110.64 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.07 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 80.9%
SYRE is currently trading at $93.89, placing it 80.9% of the way from its 52-week low of $23.01 to its 52-week high of $110.64. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 130 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Spyre Therapeutics, Inc. (SYRE) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to SYRE, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between SYRE shares and USD.
SYRE Shares to USD
1.00 SYRE shares = 93.885 USD
Calculations are estimates based on the latest available price and are for reference only.